Patents by Inventor Andrew Cansfield

Andrew Cansfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8883820
    Abstract: The invention relates to compounds of formula (I); wherein X and R1 to R5 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of Itk or PI3K, for the treatment or prophylaxis of immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: November 11, 2014
    Assignee: Cellzome Ltd.
    Inventors: Francis Wilson, Nigel Ramsden, Kathryn Bell, Andrew Cansfield, Svenja Burckhardt, Jess Taylor, Mihiro Sunose, David Middlemiss
  • Patent number: 8153389
    Abstract: The present invention relates to methods for the identification of a PI3K interacting compound using phenylthiazole ligand 1.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: April 10, 2012
    Assignee: CellZone AG
    Inventors: Giovanna Bergamini Moore, Andrew Cansfield, Nigel Ramsden, Gitte Neubauer
  • Patent number: 8106236
    Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: January 31, 2012
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Yan Zhang, Chih Yung Ho
  • Publication number: 20110111972
    Abstract: The present invention relates to methods wherein a PI3K interacting compound is identified by incubating a PI3K containing protein preparation with phenyl thiazole ligand 1.
    Type: Application
    Filed: February 3, 2009
    Publication date: May 12, 2011
    Applicant: CELLZOME AG
    Inventors: Andrew Cansfield, Giovanna Bergamini Moore, Gitte Neubauer
  • Patent number: 7825160
    Abstract: The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: November 2, 2010
    Assignee: Cellzome Limited
    Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline Leformal, Andrew Cansfield, Svenja Burckhardt
  • Publication number: 20100227800
    Abstract: The invention relates to compounds of formula (I); wherein X and R1 to R5 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of Itk or PI3K, for the treatment or prophylaxis of immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.
    Type: Application
    Filed: August 30, 2007
    Publication date: September 9, 2010
    Applicant: CELLZOME LIMITED
    Inventors: Francis Wilson, Nigel Ramsden, Kathryn Bell, Andrew Cansfield, Svenja Burckhardt, Jess Taylor, Mihiro Sunose, David Middlemiss
  • Publication number: 20100055711
    Abstract: The present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, c) incubating the phenylthiazole ligand 1-PI3K complex with a given compound, and d) determining whether the compound is able to separate PI3K from the immobilized phenylthiazole ligand 1. Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support and with a given compound under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and c) detecting the phenylthiazole ligand 1-PI3K complex formed in step b).
    Type: Application
    Filed: August 3, 2007
    Publication date: March 4, 2010
    Inventors: Giovanna Bergamini Moore, Andrew Cansfield, Nigel Ramsden, Gitte Neubauer
  • Patent number: 7557244
    Abstract: The present invention relates to compounds having the general Formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, and R10 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: July 7, 2009
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernadez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Chih Yung Ho, Yan Zhang
  • Publication number: 20090118289
    Abstract: The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.
    Type: Application
    Filed: October 21, 2005
    Publication date: May 7, 2009
    Applicant: CELLZOME AG
    Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline Leformal, Andrew Cansfield, Svenja Burckhardt
  • Publication number: 20070293567
    Abstract: The present invention relates to compounds having the general Formula (I) with the definitions of X, Y, R1, R2, R3, R4 R9, and R10 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.
    Type: Application
    Filed: April 20, 2007
    Publication date: December 20, 2007
    Inventors: Francis WILSON, Alison Reid, Valerie Reader, Richard Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Chih Ho, Yan Zhang
  • Publication number: 20070275961
    Abstract: Compounds of formula (IA) or (AB) are kinase inhibitors, especially of CDK2, and/or PDK1 and/or CHK1: wherein Ring A is an optionally substituted aryl, heteroaryl, carbocyclic or heterocyclic radical, Alk represents an optionally substituted clivaient C1-C6 alkylene radical; n is 0 or 1; Q represents a radical of formula -(Alk1)p-(X),(Alk2)s-Z wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring, p, r and s are 0 or 1, and Alk1, Alk2, X, are as described in the specification, and R1 represents a radical 3 4 3 (CYC)k-(Alk3)a-(Y)b-(Alk4)d-B wherein k, a, b and d are 0 or 1, and Cyc, Alk3, Alk4 and B are as described in the specification.
    Type: Application
    Filed: June 2, 2004
    Publication date: November 29, 2007
    Applicant: VERNALIS (CAMBRIDGE) LIMITED.
    Inventors: Justin Bower, Andrew Cansfield, Allan Jordan, Martin Parratt, Lee Walmsley, Douglas Williamson
  • Publication number: 20070254957
    Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.
    Type: Application
    Filed: April 19, 2007
    Publication date: November 1, 2007
    Inventors: Francis WILSON, Alison Reid, Valerie Reader, Richard Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Yan Zhang, Chih Ho
  • Publication number: 20070179161
    Abstract: Compounds of formula (I) or salts, N-oxides, hydrates or solvates thereof are inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent C1-C6 alkylene radical. n is 0 or 1. Q represents a radical of formula -(Alk1)p (X)r-(Alk2)s-Z wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring; Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene radicals which may contain a —O—, —S— or —NRA— link, wherein RA is hydrogen or C1-C6 alkyl; X represents —O—, —S—, —(C?O)—, —(C?S)—, —SO2—, —SO—, —C(?O)O—, —OC(?O)—, —C(?O)NRA—, —NR AC(?O)—, —C(?S)NRA, —NRAC(?S)—, —SO2NRA—, —NRASO2—, —OC(?O)NRA—, —NRAC(?O)O—, or —NRA— wherein RA is hydrogen or C1-C6 alkyl. p, r and s are independently 0 or 1.
    Type: Application
    Filed: March 18, 2004
    Publication date: August 2, 2007
    Applicant: VERNALIS (CAMBRIDGE) LIMITED.
    Inventors: Martin Parratt, Justin Bower, Douglas Williamson, Andrew Cansfield